Type 1 Diabetes PBMC

In Stock Samples

Lot # Condition Cell Count (M) Race/Ethnicity Age Gender Country of Collection Medications Vials Price Action
77367 Diabetes Type I 50M Caucasian 57 Male United States
Skyrizi 150ml 4 times a year; Humalog insulin pump; levothyroxine 150mcg daily; atorvastatin 80 mg, losartan 25mg; zepbound glp 0.75 once a week
107 $1,109.00
77367 Diabetes Type I 10M Caucasian 57 Male United States
Skyrizi 150ml 4 times a year; Humalog insulin pump; levothyroxine 150mcg daily; atorvastatin 80 mg, losartan 25mg; zepbound glp 0.75 once a week
12 $530.00
77153 Diabetes Type I 10M Caucasian 24 Female United States
Tandem X2 Insulin Pump, Dexcom G7, Insulin: Novolog, Medical Marijuana
4 $530.00
77367 Diabetes Type I 50M Caucasian 57 Male United States
Skyrizi 150ml 4 times a year; Humalog insulin pump; levothyroxine 150mcg daily; atorvastatin 80 mg, losartan 25mg; zepbound glp 0.75 once a week
1 $1,109.00
76212 Diabetes Type I 10M Caucasian 37 Male United States
NOVOLOG 50 U/DAY
4 $530.00
76203 Diabetes Type I 10M African American 36 Male United States
NOVOLOG/ 8u in morn/evening NOVLIN PEN 30U in morn and evening
2 $530.00
75225 Diabetes Type I 10M Caucasian 23 Male United States
Insulin levetiracetam
6 $530.00
75202 Diabetes Type I 10M Caucasian 36 Female United States
Humalog Insulin Pump Levothyroxine 0.175 mcg po QD Iron 65mg QD Multivitamin QD Calcium 600 QD D3 Qweek Biotin QD
8 $530.00
75055 Diabetes Type I 10M Caucasian 36 Female United States
Lantus 24units in the morning Humalog PRN with meal
3 $530.00
75168 Diabetes Type I 10M Caucasian 30 Female United States
Lantus and Humalog
8 $530.00

Type 1 Diabetes PBMC for Autoimmune Diabetes Research

Type 1 Diabetes PBMC products are sourced from IRB-consented donors clinically diagnosed with type 1 diabetes (T1D), processed within 24 hours of collection and cryopreserved in CryoStor CS10. These peripheral blood mononuclear cells support autoreactive T cell work, immunophenotyping and functional assays.

T1D Autoimmunity and Why PBMC

Type 1 diabetes is an autoimmune disease in which insulin-producing pancreatic beta cells are selectively destroyed. This is mechanistically distinct from type 2 diabetes, which is metabolic rather than autoimmune.

  • Autoreactive CD8+ and CD4+ T cells drive beta cell destruction, and islet-infiltrating specificities have peripheral counterparts detectable in blood
  • Islet autoantibodies against GAD65, IA-2, insulin and ZnT8 are the clinical markers of the autoimmune process, and autoantibody number predicts progression in at-risk individuals
  • HLA class II haplotypes, principally DR3-DQ2 and DR4-DQ8, confer the largest genetic risk, with additional contributions from loci including INS, PTPN22 and IL2RA
  • Regulatory T cell function and the balance between effector and regulatory compartments is a long-standing focus and a target for immunotherapy
  • Because pancreatic tissue is inaccessible in living donors, PBMC are the primary route to studying the human autoimmune response in T1D
  • PBMC support tetramer-based antigen-specific detection, high-parameter flow cytometry, single-cell sequencing, Treg suppression assays and ex vivo stimulation

Donor Stratification Available

  • Islet autoantibody status and specificity where available, including GAD65 and IA-2
  • Time since diagnosis: new-onset versus long-standing disease
  • HLA class II genotype where typed
  • Glycaemic control by most recent HbA1c where available
  • Insulin delivery method, including pump versus multiple daily injection
  • Presence of diabetic complications or comorbid autoimmune disease such as celiac disease or autoimmune thyroid disease
  • Matched healthy controls available

Product Features

  • Research Use Only (RUO), cryopreserved PBMC
  • Clinically confirmed T1D donors
  • Available in cell counts ranging from 5 million to 2 billion
  • Processed within 24 hours of collection
  • Stored using CryoStor® CS10 freezing media
  • IRB-approved protocols and electronic informed consent
  • Screen LeukoLot™ available prior to bulk orders

De-identified Donor Data

  • Verified T1D diagnosis
  • Donor demographics: age, sex assigned at birth, race/ethnicity
  • Self-reported allergies and infectious disease history
  • Medication history including insulin regimen
  • Additional T1D-specific data available upon request

Applications

  • Autoreactive T cell identification, including tetramer-based antigen-specific detection
  • High-parameter immunophenotyping of T cell, B cell and monocyte subsets
  • Regulatory T cell frequency and suppression assays
  • TCR repertoire sequencing and clonality analysis
  • Single-cell and bulk transcriptomic profiling
  • Immunotherapy and tolerance induction mechanism-of-action studies
  • Genomic DNA extraction for HLA and risk-locus genotyping
  • Biomarker discovery against matched healthy controls

Other Type 1 Diabetes Specimen Types

Compliance and Quality Assurance

  • IRB-approved collections and protocols
  • 21 CFR Part 11 – compliant e-consent system
  • HIPAA-compliant donor data protection

Ordering & Customization

Type 1 Diabetes PBMC samples are shipped on dry ice and available in custom aliquots. For pricing, availability, international orders or regulatory requirements, please contact learnmore@sanguinebio.com to confirm documentation and compliance needs. To browse PBMC from other disease states and check live stock status, visit our human PBMC page.

Protocols & Documentation

  • PBMC Isolation from Whole Blood

    Standard operating procedure for isolating peripheral blood mononuclear cells from whole blood using density-gradient separation.

    Download
  • Immune Cell Isolation

    Guidelines for isolating immune cell populations with validated enrichment steps, purity checkpoints, and documentation.

    Download
  • Choosing the Right PBMC Configuration

    Reference guide comparing PBMC formats, cryopreservation states, and study-fit recommendations for your application.

    Download
  • Thawing Cryopreserved PBMC

    Validated thawing protocol to recover viable cryopreserved PBMCs while minimizing activation and loss of function.

    Download
  • Informed Consent Form (ICF)

    Available upon request — confirms donor consent for research use and downstream commercialization.

PBMC

Frequently Asked Questions

Showing 1–12 of 30 results

Are samples IRB approved?

1 Answer

YES – All collections are conducted under IRB-approved protocols and electronic informed consent. Sanguine utilizes Advarra and WCG IRB for oversight.

YES – all our products are research use only (RUO).

Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.

Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.

Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.

Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.

YES – we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.

Each sample from a different individual – Unique donor means each sample comes from a different person, ensuring biological diversity in your study.

YES – Unique donors can be specified and guaranteed based on your requirements.

For information about sample quality, please see: Quality and Compliance

YES – “IRB-approved collection protocols” and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.

1
×

Ask a Question

Need a custom PBMC cohort?

Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.

More Information